CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 63 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.3%.
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 1,875,209 | $28,203,000 | 1.68% |
| Opaleye Management Inc. | 207,000 | $3,113,000 | 1.13% |
| Perceptive Advisors | 2,587,953 | $38,922,000 | 1.05% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $2,121,000 | 0.64% |
| Orbimed Advisors | 2,039,282 | $30,671,000 | 0.58% |
| Eventide Asset Management | 947,000 | $14,243,000 | 0.47% |
| Novo Holdings A/S | 135,009 | $2,031,000 | 0.35% |
| Baker Brothers Advisors | 175,000 | $2,632,000 | 0.02% |
| Polar Capital LLP | 90,382 | $1,359,000 | 0.01% |
| Point72 Asset Management, L.P. | 132,000 | $1,985,000 | 0.01% |